Do care pathways help us choose wisely in the setting of neoadjuvant therapy for breast cancer? Results of a pre-post analysis.

e17539 Background: Guidelines suggest that neoadjuvant therapy (NAT) should be an option for any breast cancer patient to whom adjuvant therapy would be offered. Studies show that those with aggressive subtypes (TNBC, Her2+) receive the most benefit from NAT in terms of pCR rate. As coordination of NAT can be complex, many centres have implemented care pathways and databases to track these patients. Still, it is unknown whether a care pathway may improve patient selection for NAT. This study aimed to compare breast cancer patients selected for NAT at BCCA Vancouver both pre- and post-implementation of a care pathway program, and to evaluate wait times and pCR rates. Methods: Breast cancer patients referred for consideration of NAT from May 2012 - May 2013 (retrospective cohort) and May 17, 2013 - September 2014 (prospective cohort) were included in a secure database. Wait times and tumour characteristics were assessed and are reported using descriptive statistics. Results: 155 cases were referred for cons...